Germany · Delayed Price · Currency is EUR WuXi Biologics Statistics
Total Valuation
WuXi Biologics has a market cap or net worth of EUR 14.43 billion. The enterprise value is 14.02 billion.
| Market Cap | 14.43B |
| Enterprise Value | 14.02B |
Important Dates
The last earnings date was Wednesday, November 19, 2025.
| Earnings Date | Nov 19, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | 4.12B |
| Shares Outstanding | n/a |
| Shares Change (YoY) | -2.55% |
| Shares Change (QoQ) | -0.30% |
| Owned by Insiders (%) | 0.73% |
| Owned by Institutions (%) | 32.50% |
| Float | 3.59B |
Valuation Ratios
The trailing PE ratio is 28.92 and the forward PE ratio is 22.42.
| PE Ratio | 28.92 |
| Forward PE | 22.42 |
| PS Ratio | 6.05 |
| PB Ratio | 2.47 |
| P/TBV Ratio | 2.82 |
| P/FCF Ratio | 68.99 |
| P/OCF Ratio | 21.21 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 16.65, with an EV/FCF ratio of 67.07.
| EV / Earnings | 28.12 |
| EV / Sales | 5.78 |
| EV / EBITDA | 16.65 |
| EV / EBIT | 21.11 |
| EV / FCF | 67.07 |
Financial Position
The company has a current ratio of 2.88, with a Debt / Equity ratio of 0.10.
| Current Ratio | 2.88 |
| Quick Ratio | 2.40 |
| Debt / Equity | 0.10 |
| Debt / EBITDA | 0.73 |
| Debt / FCF | 2.90 |
| Interest Coverage | 31.72 |
Financial Efficiency
Return on equity (ROE) is 10.50% and return on invested capital (ROIC) is 6.64%.
| Return on Equity (ROE) | 10.50% |
| Return on Assets (ROA) | 5.89% |
| Return on Invested Capital (ROIC) | 6.64% |
| Return on Capital Employed (ROCE) | 10.57% |
| Revenue Per Employee | 189,905 |
| Profits Per Employee | 39,737 |
| Employee Count | 12,575 |
| Asset Turnover | 0.34 |
| Inventory Turnover | 6.36 |
Taxes
In the past 12 months, WuXi Biologics has paid 146.49 million in taxes.
| Income Tax | 146.49M |
| Effective Tax Rate | 20.03% |
Stock Price Statistics
The stock price has increased by +91.62% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | +91.62% |
| 50-Day Moving Average | 3.99 |
| 200-Day Moving Average | 3.27 |
| Relative Strength Index (RSI) | 31.91 |
| Average Volume (20 Days) | 1,948 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, WuXi Biologics had revenue of EUR 2.38 billion and earned 498.77 million in profits. Earnings per share was 0.12.
| Revenue | 2.38B |
| Gross Profit | 1.02B |
| Operating Income | 652.56M |
| Pretax Income | 731.49M |
| Net Income | 498.77M |
| EBITDA | 808.84M |
| EBIT | 652.56M |
| Earnings Per Share (EPS) | 0.12 |
Balance Sheet
The company has 1.49 billion in cash and 607.03 million in debt, giving a net cash position of 883.45 million.
| Cash & Cash Equivalents | 1.49B |
| Total Debt | 607.03M |
| Net Cash | 883.45M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 5.83B |
| Book Value Per Share | 1.31 |
| Working Capital | 1.90B |
Cash Flow
In the last 12 months, operating cash flow was 680.11 million and capital expenditures -471.01 million, giving a free cash flow of 209.11 million.
| Operating Cash Flow | 680.11M |
| Capital Expenditures | -471.01M |
| Free Cash Flow | 209.11M |
| FCF Per Share | n/a |
Margins
Gross margin is 42.65%, with operating and profit margins of 27.38% and 20.92%.
| Gross Margin | 42.65% |
| Operating Margin | 27.38% |
| Pretax Margin | 30.69% |
| Profit Margin | 20.92% |
| EBITDA Margin | 33.93% |
| EBIT Margin | 27.38% |
| FCF Margin | 8.77% |
Dividends & Yields
WuXi Biologics does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 2.55% |
| Shareholder Yield | 2.55% |
| Earnings Yield | 3.46% |
| FCF Yield | 1.45% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on November 16, 2020. It was a forward split with a ratio of 3.
| Last Split Date | Nov 16, 2020 |
| Split Type | Forward |
| Split Ratio | 3 |
Scores
WuXi Biologics has an Altman Z-Score of 5.11 and a Piotroski F-Score of 8.
| Altman Z-Score | 5.11 |
| Piotroski F-Score | 8 |